Dr. Sven Zimmermann has more than 25 years of experience in biotech ,finance, governance, and corporate leadership. As a senior executive he successfully managed the strategic development of several advanced clinical stage biotech companies. He is currently the CEO of Inotrem SA and benefits from a wide ranging experience in corporate finance and capital raisings. He has also been involved in several exits such as Novimmune’s asset sale to Swedish Orphan Biovitrum, Auris Medical’s IPO on Nasdaq, Aimago’s sale to Novadaq, as well as the acquisition of Epiontis by Precision for Medicine and of PregLem by Gedeon Richter.
Dr. Zimmermann began his career in the financial industry working for UBS as an Equity Analyst. He obtained a PhD in molecular biology from the University of Zurich and spent several years as a researcher in the fields of oncology, and virology.
